Please assess the completion status of the following clinical trial:

Trial Title: Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed perianal high-grade squamous intraepithelial lesions (HSIL) within the past 12 weeks~  * The perianal skin (i.e., perianus) is defined as extending radially 5 cm from the anal verge~ * Lesions must cover a surface area of ≥ 3 square centimeters~ * Lesions extending outside the perianus (e.g., vulvar lesions on the posterior perineum bordering the perianus) are allowed~* Serologic documentation of HIV infection AND meets 1 of the following criteria:~  * Has been on stable highly active anti-retroviral therapy (HAART) for ≥ 12 weeks prior to study entry~ * Has a CD4 count of \> 200/mm³ AND is not receiving anti-retroviral therapy OR is currently receiving a non-HAART\* anti-retroviral regimen with no plans to initiate HAART within the next 12 weeks NOTE: \* A non-HAART regimen is considered to be a therapy that does not include a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor~* No untreated invasive cancer of the lower genital tract~* No concurrent neoplasia requiring cytotoxic therapy~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Life expectancy ≥ 3 months~* Hemoglobin ≥ 8 g/dL~* ANC ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Creatinine \< 1.5 times upper limit of normal (ULN)~* Total or conjugated (direct) bilirubin ≤ 2.5 times ULN~* AST and ALT ≤ 3 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* No acute, opportunistic infection other than oral thrush, yeast vaginitis, or genital herpes within the past 14 days~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior ablative or surgical treatment of perianal dysplasia~* At least 4 weeks since prior topical treatment for perianal dysplasia~  * If any prior treatment caused significant trauma to ther area, healing should occur prior to starting treatment~* More than 14 days since prior acute treatment for infection (other than for oral thrush, yeast vaginitis, or genital herpes) or other serious medical illness~* No concurrent corticosteroids other than replacement doses~* No other concurrent investigational drugs except IND-approved anti-retroviral agents~* No concurrent systemic cytotoxic chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cidofovir (Type: EXPERIMENTAL): 1.0% topical cidofovir cream

Based on this trial design, predict the completion outcome and termination type (if applicable).